Holders — by stockHoldings — by fund
Logos Global Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001792126
$2.32B
disclosed book value
68
positions
9.6%
largest position share
Positions, as of 2026-06-30
top 68 of 68 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ERASERASCA INC | 12.2M | $222.6M | 9.6% |
| 2 | ABVXABIVAX SA | 1.0M | $136.5M | 5.9% |
| 3 | RVMDREVOLUTION MEDICINES INC | 700,000 | $131.1M | 5.6% |
| 4 | IDYAIDEAYA BIOSCIENCES INC | 3.0M | $111.8M | 4.8% |
| 5 | BNTXBIONTECH SE | 1.0M | $94.4M | 4.1% |
| 6 | VERAVERA THERAPEUTICS INC | 2.2M | $94.4M | 4.1% |
| 7 | TNGXTANGO THERAPEUTICS INC | 2.9M | $89.1M | 3.8% |
| 8 | PRAXPRAXIS PRECISION MEDICINES I | 260,000 | $87.0M | 3.7% |
| 9 | CLDXCELLDEX THERAPEUTICS INC NEW | 2.1M | $78.1M | 3.4% |
| 10 | DNTHDIANTHUS THERAPEUTICS INC | 800,000 | $78.0M | 3.4% |
| 11 | CGONCG ONCOLOGY INC | 1.0M | $71.0M | 3.1% |
| 12 | IRONDISC MEDICINE INC | 875,000 | $64.0M | 2.8% |
| 13 | MAZEMAZE THERAPEUTICS INC | 1.9M | $57.7M | 2.5% |
| 14 | DYNDYNE THERAPEUTICS INC | 2.5M | $56.6M | 2.4% |
| 15 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 2.7M | $52.1M | 2.2% |
| 16 | OCULOCULAR THERAPEUTIX INC | 5.3M | $52.0M | 2.2% |
| 17 | DSGNDESIGN THERAPEUTICS INC | 3.0M | $43.4M | 1.9% |
| 18 | OLMAOLEMA PHARMACEUTICALS INC | 3.2M | $40.1M | 1.7% |
| 19 | BLTEBELITE BIO INC | 250,000 | $38.5M | 1.7% |
| 20 | ACHVACHIEVE LIFE SCIENCE INC | 5.4M | $35.4M | 1.5% |
| 21 | TRVITREVI THERAPEUTICS INC | 1.9M | $35.1M | 1.5% |
| 22 | COGTCOGENT BIOSCIENCES INC | 900,000 | $34.8M | 1.5% |
| 23 | AVBPARRIVENT BIOPHARMA INC | 1.0M | $34.7M | 1.5% |
| 24 | CRESCENT BIOPHARMA INC. | 1.9M | $34.2M | 1.5% |
| 25 | CMPSCOMPASS PATHWAYS PLC | 2.3M | $31.8M | 1.4% |
| 26 | MLYSMINERALYS THERAPEUTICS INC | 1.1M | $28.3M | 1.2% |
| 27 | REPLREPLIMUNE GROUP INC | 2.5M | $27.7M | 1.2% |
| 28 | XENEXENON PHARMACEUTICALS INC | 450,000 | $27.2M | 1.2% |
| 29 | GPCRSTRUCTURE THERAPEUTICS INC | 500,000 | $26.8M | 1.2% |
| 30 | IMVTIMMUNOVANT INC | 665,000 | $25.6M | 1.1% |
| 31 | JBIOJADE BIOSCIENCES INC | 1.1M | $25.0M | 1.1% |
| 32 | ELVNENLIVEN THERAPEUTICS INC | 465,000 | $23.6M | 1% |
| 33 | MANEVERADERMICS INC | 180,000 | $22.1M | 1% |
| 34 | AVTXAVALO THERAPEUTICS INC | 1.1M | $21.3M | 0.9% |
| 35 | RCUSARCUS BIOSCIENCES INC | 650,000 | $20.0M | 0.9% |
| 36 | SMMTSUMMIT THERAPEUTICS INC | 1.4M | $19.7M | 0.8% |
| 37 | IMCRIMMUNOCORE HLDGS PLC | 600,000 | $19.1M | 0.8% |
| 38 | LBRXLB PHARMACEUTICALS INC | 585,000 | $19.0M | 0.8% |
| 39 | NERVMINERVA NEUROSCIENCES INC | 3.3M | $18.3M | 0.8% |
| 40 | FTHFAETH THERAPEUTICS INC | 722,020 | $18.1M | 0.8% |
| 41 | CRISPR THERAPEUTICS AG | 300,000 | $16.4M | 0.7% |
| 42 | DBVTDBV TECHNOLOGIES S A | 915,000 | $15.0M | 0.6% |
| 43 | PBLSPARABILIS MEDICINES INC | 525,000 | $14.4M | 0.6% |
| 44 | RYTMRHYTHM PHARMACEUTICALS INC | 125,000 | $13.9M | 0.6% |
| 45 | VORVOR BIOPHARMA INC | 650,000 | $12.0M | 0.5% |
| 46 | SRRKSCHOLAR ROCK HLDG CORP | 200,000 | $11.0M | 0.5% |
| 47 | IMMXIMMIX BIOPHARMA INC | 1.0M | $10.3M | 0.4% |
| 48 | QTTBQ32 BIO INC | 800,000 | $10.2M | 0.4% |
| 49 | ODTXODYSSEY THERAPEUTICS INC | 521,736 | $9.8M | 0.4% |
| 50 | ANNXANNEXON INC | 1.5M | $8.6M | 0.4% |
| 51 | EDITEDITAS MEDICINE INC | 2.2M | $7.2M | 0.3% |
| 52 | RLAYRELAY THERAPEUTICS INC | 350,000 | $6.5M | 0.3% |
| 53 | ACADACADIA PHARMACEUTICALS INC | 250,000 | $6.3M | 0.3% |
| 54 | AMLXAMYLYX PHARMACEUTICALS INC | 350,000 | $6.3M | 0.3% |
| 55 | HELPCYBIN INC | 750,000 | $5.0M | 0.2% |
| 56 | OKURONKURE THERAPEUTICS INC | 963,855 | $4.4M | 0.2% |
| 57 | TENXTENAX THERAPEUTICS INC | 300,000 | $4.4M | 0.2% |
| 58 | DFTXDEFINIUM THERAPEUTICS INC | 80,000 | $3.8M | 0.2% |
| 59 | UNCYUNICYCIVE THERAPEUTICS INC | 473,563 | $2.2M | 0.1% |
| 60 | PTNPALATIN TECHNOLOGIES INC | 130,000 | $1.4M | 0.1% |
| 61 | UNIQURE NV | 30,000 | $1.4M | 0.1% |
| 62 | JATT II ACQUISITION CORP | 100,000 | $1.1M | 0% |
| 63 | RESEARCH ALLIANCE CORP III | 100,000 | $1.1M | 0% |
| 64 | ACRSACLARIS THERAPEUTICS INC | 200,000 | $1.1M | 0% |
| 65 | LGVNLONGEVERON INC | 1.3M | $904,761 | 0% |
| 66 | GUTSFRACTYL HEALTH INC | 1.0M | $794,400 | 0% |
| 67 | SEPNSEPTERNA INC | 23,548 | $788,623 | 0% |
| 68 | AMANAT ACQUISITION CORP | 50,000 | $508,000 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.